Matt David, MDExecutive Vice President, Chief Financial Officer at CorMedix Inc.
Matt is currently the Executive Vice President and Chief Financial Officer of CorMedix (Nasdaq: CRMD), where he leads the Company’s finance and investor relations activities. Prior to joining CorMedix, Matt was Head of Strategy at Ovid Therapeutics, a biopharmaceutical company focused on rare neurological disorders. Prior to Ovid, Matt served as a Strategic Advisor to Frequency Therapeutics, advising on financing, investor relations and strategic initiatives. Matt spent the majority of his career as an investment banker specialized in the life sciences sector, including at Piper Jaffray, Thomas Weisel Partners, Ferghana Partners and Bank of America Merrill Lynch. As part of his experience as an investment banker, Matt has advised on a broad range of capital raising and strategic transactions. Earlier in his career, Matt was part of the equity research team at Lehman Brothers, focusing on Large Pharma. Matt received his M.D. from NYU School of Medicine and his undergraduate degree from Dartmouth College.